- Published on
Infectious Disease And Microbiology – Empyema
Empyema is defined as the accumulation of purulent (pus-containing) fluid within the pleural cavity. It most commonly develops as a complication of bacterial pneumonia but may also arise following thoracic surgery, trauma, esophageal perforation, or subdiaphragmatic infections. In children, empyema is usually secondary to pneumonia—most often caused by Streptococcus pneumoniae—and tends to have a better prognosis than in adults, although management principles are similar. Overall, pleural effusions occur in up to 57% of pneumonia cases, but only about 1–2% progress to empyema. The condition affects individuals of all ages, with higher prevalence in the elderly and in children, and occurs more frequently in males.
Several risk factors predispose individuals to empyema, including diabetes mellitus, alcoholism, substance abuse, rheumatoid arthritis, chronic lung disease, poor dental hygiene, malignancy, and prior thoracic surgery. Conditions that increase the risk of aspiration are particularly associated with anaerobic infections. Prevention focuses on appropriate treatment of pneumonia, adherence to surgical infection control practices, and vaccination (especially pneumococcal vaccination).
The development of empyema progresses through three stages. The exudative stage involves inflammation and fluid accumulation in the pleural space. This is followed by the fibrinopurulent stage, characterized by fibrin deposition and pus formation. Finally, the organizing stage occurs, where fibroblasts proliferate and collagen is deposited, potentially leading to pleural thickening and restricted lung expansion. The causative organisms vary depending on whether the infection is community-acquired or hospital-acquired. Community-acquired empyema commonly involves streptococci, staphylococci, anaerobes, and Enterobacteriaceae, while hospital-acquired cases are more often caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, enterococci, and other resistant organisms.
Clinically, patients often present with a history of pneumonia or thoracic procedures, along with symptoms such as fever, chest pain, and shortness of breath. In elderly or immunocompromised patients, symptoms may be subtle, including weight loss or anemia. On physical examination, findings may include dullness to percussion, decreased tactile fremitus, and absent breath sounds over the affected area, although small effusions may not produce obvious signs.
Diagnosis is confirmed through thoracentesis, with the presence of pus in the pleural space being definitive. Laboratory evaluation includes complete blood count and inflammatory markers such as C-reactive protein. Pleural fluid analysis is essential and typically shows low pH (<7.2), high white blood cell count, and positive Gram stain or culture. Imaging plays a key role: chest X-ray identifies pleural effusion, ultrasound helps localize fluid and guide drainage, and CT scan can distinguish empyema from lung abscess (notably showing the “split pleura” sign).
The differential diagnosis includes other causes of pleural effusion, lung abscess, and pneumonia. Management requires prompt initiation of antimicrobial therapy along with drainage of the infected fluid, usually via chest tube. Antibiotic regimens differ based on whether the infection is community- or hospital-acquired and should cover likely pathogens, including anaerobes and resistant organisms where appropriate. Adjunctive treatments include adequate hydration, nutritional support, and, in some cases, intrapleural fibrinolytic therapy to improve drainage.
In cases where drainage is incomplete or complications arise, surgical intervention may be necessary. Options include video-assisted thoracoscopic surgery (VATS), thoracotomy with decortication, or other open surgical procedures. Most patients require hospitalization for intravenous antibiotics and monitoring. Follow-up involves continued antibiotic therapy for 2–4 weeks, monitoring inflammatory markers, and ensuring adequate drainage. Chest tubes are typically removed once drainage decreases and fluid clears.
The prognosis of empyema varies depending on patient factors and timeliness of treatment. While many patients recover with appropriate management, mortality rates range from 7% to 33% within one year and may exceed 50% in patients with significant comorbidities. Complications include pleural thickening, pulmonary fibrosis, pneumothorax, bronchopleural fistula, respiratory failure, septic shock, and, in rare cases, empyema necessitatis.
0 Comments
